Title:
RADIOLABELED COMPOUND AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/008556
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide a drug which specifically binds to PSMA, which is effective in treatment and diagnosis of tumors or cancers that express PSMA, such as treatment and diagnosis of prostate cancer, especially castration-resistant prostate cancer (CRPC), and further especially castration-resistant prostate cancer with metastasis (mCRPC), and which does not produce any side effects due to accumulation in the kidney and salivary glands. The present invention provides a radiolabeled compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The present invention is represented by formula (I). (I) [In the formula, each symbol is as defined in the description.]
Inventors:
SHIRAKAMI YOSHIFUMI (JP)
KANEDA KAZUKO (JP)
KADONAGA YUICHIRO (JP)
WATABE TADASHI (JP)
TOYOSHIMA ATSUSHI (JP)
FUKASE KOICHI (JP)
YOSHIYA TAKU (JP)
KANEDA KAZUKO (JP)
KADONAGA YUICHIRO (JP)
WATABE TADASHI (JP)
TOYOSHIMA ATSUSHI (JP)
FUKASE KOICHI (JP)
YOSHIYA TAKU (JP)
Application Number:
PCT/JP2022/029283
Publication Date:
February 02, 2023
Filing Date:
July 29, 2022
Export Citation:
Assignee:
UNIV OSAKA (JP)
International Classes:
C07K4/00; A61K38/08; A61K51/08; A61P13/08; A61P35/00; C07B59/00; C07C273/18; C07C275/16; C07F5/02; G01T1/161
Domestic Patent References:
| WO2019027059A1 | 2019-02-07 | |||
| WO2016062370A1 | 2016-04-28 | |||
| WO2019176505A1 | 2019-09-19 | |||
| WO2015055318A1 | 2015-04-23 | |||
| WO2010014933A2 | 2010-02-04 | |||
| WO2017070482A2 | 2017-04-27 |
Foreign References:
| JP2018531243A | 2018-10-25 | |||
| EP3805250A1 | 2021-04-14 | |||
| JP2021125774A | 2021-08-30 |
Other References:
SHIRAKAMI YOSHIFUMI, WATABE TADASHI, OBATA HONOKA, KANEDA KAZUKO, OOE KAZUHIRO, LIU YUWEI, TERAMOTO TAKAHIRO, TOYOSHIMA ATSUSHI, S: "Synthesis of [211At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution", SCIENTIFIC REPORTS, NATURE PUBLISHING GROUP, US, vol. 11, no. 1, 21 June 2021 (2021-06-21), US , pages 12982 - 7, XP093029630, ISSN: 2045-2322, DOI: 10.1038/s41598-021-92476-6
CARDINALE JENS, ROSCHER MAREIKE, SCHÄFER MARTIN, GEERLINGS MAX, BENEŠOVÁ MARTINA, BAUDER-WÜST ULRIKE, REMDE YVONNE, EDER MATTHIAS,: "Development of PSMA-1007-Related Series of 18 F-Labeled Glu-Ureido-Type PSMA Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 63, no. 19, 8 October 2020 (2020-10-08), US , pages 10897 - 10907, XP093029634, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b01479
J NUCL MED, vol. 57, 2016, pages 1569 - 75
NUCL MED BIOL, vol. 94-95, 2021, pages 67 - 80
CARDINALE JENS, ROSCHER MAREIKE, SCHÄFER MARTIN, GEERLINGS MAX, BENEŠOVÁ MARTINA, BAUDER-WÜST ULRIKE, REMDE YVONNE, EDER MATTHIAS,: "Development of PSMA-1007-Related Series of 18 F-Labeled Glu-Ureido-Type PSMA Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 63, no. 19, 8 October 2020 (2020-10-08), US , pages 10897 - 10907, XP093029634, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b01479
J NUCL MED, vol. 57, 2016, pages 1569 - 75
NUCL MED BIOL, vol. 94-95, 2021, pages 67 - 80
Attorney, Agent or Firm:
TAKASHIMA, Hajime (JP)
Download PDF:
Previous Patent: THERAPEUTIC AGENT FOR ISCHEMIC DISEASE
Next Patent: COMPOUND HAVING ANTICANCER EFFECT
Next Patent: COMPOUND HAVING ANTICANCER EFFECT